US Pharma MarketingIonis wins FDA label expansion for potential blockbuster triglycerides indication
Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Ionis landed an FDA approval on Wednesday that will greatly expand its commercial opportunity for Tryngolza.
The antisense drug may now be used to treat patients who have severely high levels of fat molecules called ...
Source: Endpoints News